Similarly, a study published in The Journal of Clinical Oncology in 2020 reported that among patients with BRCA1/2-mutated ovarian cancer who received niraparib, another FDA-approved PARPi, the objective response rate was 73%, and the median progression-free survival was 12.9 months (Turner et al. 2021). This evidence concerns the gene BRCA1 and ovarian cancer.